Mass psychogenic response to human papillomavirus vaccination

• 1 SAEFVIC, Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, VIC.
• 2 Department of Paediatrics, University of Melbourne, Melbourne, VIC.
• 3 Infectious Diseases Unit and Immunisation Service, Department of General Medicine, Royal Children’s Hospital, Melbourne, VIC.
• 4 Victorian Department of Human Services, Melbourne, VIC.
• 5 National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.
• 6 Department of Paediatric Neurology, Monash Medical Centre, Melbourne, VIC.

---

• 1. Australian Institute of Health and Welfare. Cancer in Australia 2001. Canberra: AIHW, 2004. (AIHW Cat. No. CAN 23; Cancer series No. 28.)
• 2. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255.
• 3. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
• 4. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-1702.
• 5. Clements CJ. Mass psychogenic illness after vaccination. Drug Saf 2003; 26: 599-604.
• 6. Tanne JH. Questions over human papillomavirus vaccine in the US and Australia. BMJ 2007; 334: 1182-1183.
• 7. Clements CJ. Gardasil and mass psychogenic illness. Aust N Z J Public Health 2007; 31: 387.